SCHEMBL314438

SCHEMBL314438

Nc1ccc(-c2ccccc2[O])cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
HSD17B10 Q99714 2/20 0.50
TAAR1 Q96RJ0 1/20 0.50
ALDH1A1 P00352 4/20 0.46
TP53 P04637 2/20 0.46
NCOA1 Q15788 3/20 0.42
NCOA3 Q9Y6Q9 2/20 0.42
PRKCZ Q05513 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
TSHR P16473 2/20 0.40
MAPK1 P28482 1/20 0.40
KDR P35968 3/20 0.39
KIT P10721 2/20 0.39
FLT3 P36888 2/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
PTPRC P08575 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9246341 0.82 HSD17B10 (0.63) CYP3A4TDP1HSD17B10TAAR1ALDH1A1
SCHEMBL9937968 0.80 ALDH1A1 (0.47) CYP3A4TDP1HSD17B10TAAR1ALDH1A1
SCHEMBL13941274 0.79 HSD17B10 (0.60) CYP3A4TDP1HSD17B10TAAR1ALDH1A1
SCHEMBL30208583 0.79 HSD17B10 (0.68) CYP3A4TDP1HSD17B10TAAR1ALDH1A1
SCHEMBL29948076 0.79 HSD17B10 (0.60) CYP3A4TDP1HSD17B10TAAR1ALDH1A1
SCHEMBL29118206 0.79 HSD17B10 (0.68) CYP3A4TDP1HSD17B10TAAR1ALDH1A1
SCHEMBL11898487 0.79 ALDH1A1 (0.42) TDP1HSD17B10ALDH1A1SMN1; SMN2NPC1
SCHEMBL60313 0.79 ALDH1A1 (0.48) TDP1HSD17B10ALDH1A1SMN1; SMN2MAPK1
Ethane SCHEMBL28326373 0.77 CYP3A4 (0.57) CYP3A4TDP1HSD17B10TAAR1ALDH1A1
SCHEMBL223708 0.77 PTGS2 (0.46) TDP1HSD17B10ALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093287-B2 Inhibitors of matrix metalloproteinases UNIVERSITY OF NOTRE DAME DU LAC (US) 2012-01-10 US disclosed
US-20110224275-A1 INHIBITORS OF MATRIX METALLOPROTEINASES NOTRE DAME UNIVERSITY (US) 2011-09-15 US disclosed
US-7928127-B2 Inhibitors of matrix metallaproteinases NOTRE DAME UNIVERSITY (US) 2011-04-19 US disclosed
US-20090005420-A1 Inhibitors of Matrix Metallaproteinases NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005420-A1 Inhibitors of Matrix Metallaproteinases MMP9, MMP1, MMP2 CYP3A4 2685/4885TDP1 2917/4885HSD17B10 660/4885
US-20110224275-A1 INHIBITORS OF MATRIX METALLOPROTEINASES MMP9, MMP1, MMP2 CYP3A4 2085/4885TDP1 1708/4885HSD17B10 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.